Information Provided By:
Fly News Breaks for March 31, 2015
HZNP, HPTX
Mar 31, 2015 | 07:47 EDT
Brean Capital believes Horizon Pharma's (HPZN) guidance on annualized cost savings from its deal with Hyperion Therapeutics (HPTX) is conservative. The firm noted Horizon executes well on M&A, as it paid a reasonable price for Hyperion. Brean Capital reiterated its Buy rating and raised its price target to $33 from $27 on Horizon Pharma shares.
News For HZNP;HPTX From the Last 2 Days
HZNP
Sep 24, 2018 | 06:25 EDT
After hosting a call featuring an expert focused on thyroid eye disease, also known as Graves' orbitopathy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $25 price target. The analyst says commentary from the expert heightened his confidence that Horizon's teprotumumab "will emerge as a paradigm-shifting option" in the broader thyroid eye disease treatment landscape. The expert views teprotumumab not only as a means of avoiding surgical intervention but also as a potential option in less severe patients who are not necessarily headed for surgery, Amsellem tells investors in a research note. He believes Horizon remains well positioned for long-term annual EBITDA growth "that is solidly in the double-digits."
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.